Hirotaka Iwase

Q: What Schools Are Affiliated With Hirotaka Iwase

Hirotaka Iwase is affiliated with the following schools: Nagoya City University, Kumamoto University

Hirotaka Iwase's AcademicInfluence.com Rankings

Hirotaka Iwase

Engineering

#4947

World Rank

#6174

Historical Rank

Biomedical Engineering

#344

World Rank

#353

Historical Rank

engineering Degrees

Hirotaka Iwase

Philosophy

#6934

World Rank

#10061

Historical Rank

Logic

#4016

World Rank

#5257

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Hirotaka Iwase's Degrees

PhD Biomedical Engineering University of Tokyo
Masters Biomedical Engineering University of Tokyo
Bachelors Biomedical Engineering University of Tokyo

Why Is Hirotaka Iwase Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hirotaka Iwase's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

[Breast cancer]. (2006) (4614)
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* (2005) (294)
HDAC6 Expression Is Correlated with Better Survival in Breast Cancer (2004) (284)
Expression, Function, and Clinical Implications of the Estrogen Receptor β in Human Lung Cancers (2001) (189)
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer (2003) (173)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. (2012) (154)
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer (2008) (144)
Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas (1996) (142)
Suppression of ING1 expression in sporadic breast cancer (1999) (141)
Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer (2014) (133)
Clinical value of the wild-type estrogen receptor β expression in breast cancer (2001) (125)
Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. (2002) (118)
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. (2001) (111)
Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. (2012) (108)
Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer (2005) (106)
Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer (2006) (105)
Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. (2003) (99)
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer (2006) (95)
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients (2007) (94)
Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. (2006) (91)
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins (2010) (90)
Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells (2003) (89)
A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population (2012) (88)
Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. (2008) (87)
Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects (2015) (87)
Evaluation of Tumor Stiffness by Elastography Is Predictive for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer (2012) (84)
Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society (2010) (80)
Differential expression of oestrogen receptors in human secondary lymphoid tissues (2006) (78)
Clinical value of the wild-type estrogen receptor beta expression in breast cancer. (2001) (78)
Expression of Estrogen Receptor β Wild-type and its Variant ERβcx/β2 is Correlated with Better Prognosis in Breast Cancer (2007) (74)
Clinical significance of CYLD downregulation in breast cancer (2014) (71)
DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers (1999) (71)
High density of CD204‐positive macrophages predicts worse clinical prognosis in patients with breast cancer (2017) (71)
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers (2008) (70)
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). (2010) (67)
Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients (2011) (66)
Estrogen receptor α gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients (2009) (64)
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval (2011) (64)
Reduced Expression of the Breast Cancer Metastasis Suppressor 1 mRNA Is Correlated with Poor Progress in Breast Cancer (2006) (63)
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. (2015) (62)
Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. (1996) (61)
Microsatellite instability in sporadic human breast cancers (1996) (61)
Clinical significance of basal-like subtype in triple-negative breast cancer (2009) (60)
Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. (2000) (60)
Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer (2003) (60)
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 (2013) (60)
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer (2009) (58)
Clinical significance of E‐cadherin expression in thyroid neoplasms (2001) (57)
Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer (2015) (57)
Midkine in plasma as a novel breast cancer marker (2009) (57)
Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model (2009) (56)
A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation (2015) (55)
Clinicopathological features and treatment strategy for triple-negative breast cancer (2010) (52)
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients (2016) (52)
Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. (2018) (51)
Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. (2011) (51)
Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. (2007) (51)
Midkine as a prognostic biomarker in oral squamous cell carcinoma (2008) (51)
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance (2010) (49)
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study (2013) (49)
ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling (2015) (49)
High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level (2012) (48)
Clinical Significance of AIB1 Expression in Human Breast Cancer (2003) (47)
The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer (2016) (47)
Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? (2014) (47)
Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence (2017) (47)
Analysis of Oncogenes and Tumor Suppressor Genes in Human Breast Cancer (1993) (46)
Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis (2016) (46)
Loss of heterozygosity of the oestrogen receptor gene in breast cancer. (1995) (46)
Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression (2011) (46)
ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer. (2005) (45)
Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. (2003) (45)
The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy (2009) (42)
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast (2002) (41)
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study (2018) (41)
Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. (2007) (41)
No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. (2009) (41)
Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. (2017) (40)
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer (2018) (39)
Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens (2013) (38)
Clinical significance of bcl-2 gene expression in human breast cancer tissues (2004) (38)
NCOR1 mRNA is an independent prognostic factor for breast cancer. (2006) (37)
Molecular action of the estrogen receptor and hormone dependency in breast cancer (2003) (37)
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study (2006) (37)
Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer (2016) (37)
Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer (2008) (34)
Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion (2008) (34)
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients (2017) (33)
An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer (2014) (33)
Serum ANGPTL2 Levels Reflect Clinical Features of Breast Cancer Patients: Implications for the Pathogenesis of Breast Cancer Metastasis (2014) (33)
Association of ErbB1–4 expression in invasive breast cancer with clinicopathological characteristics and prognosis (2012) (33)
Estrogen Receptor, c‐erbB‐2 and nm23/NDP Kinase Expression in the Intraductal and Invasive Components of Human Breast Cancers (1992) (32)
Dominant‐negative Stat5 inhibits growth and induces apoptosis in T47D‐derived tumors in nude mice (2004) (32)
Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast. (2000) (31)
Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. (2017) (30)
Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery (2003) (30)
A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer (2013) (28)
C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients (2014) (27)
Microsatellite instability in in situ and invasive sporadic breast cancers of Japanese women. (1996) (27)
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast (2003) (27)
Advantage of sentinel lymph node biopsy before neoadjuvant chemotherapy in breast cancer treatment (2009) (26)
The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer (2014) (26)
Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part. 2: personal life (2017) (24)
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. (2017) (24)
Immunohistochemical analysis on biological markers in ductal carcinomain situ of the breast (2001) (23)
Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system. (2010) (22)
Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer (2008) (22)
HDAC 6 Expression Is Correlated with Better Survival in Breast Cancer (2004) (22)
Analysis of Ki‐67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer (2013) (22)
Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens (2013) (21)
Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part 1: Working style (2017) (20)
Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer (2013) (20)
p33ING1b stimulates the transcriptional activity of the estrogen receptor α via its activation function (AF) 2 domain (2003) (20)
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients (2017) (20)
Genetic and Epigenetic Alterations of the Estrogen Receptor Gene and Hormone Independence in Human Breast Cancer (1998) (20)
Estrogen receptor α mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from japanese women (2003) (20)
Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer (2015) (19)
BREAST CANCER WITH OSTEOCLAST‐LIKE MULTINUCLEATED GIANT CELLS (1984) (19)
Low phosphorylation of estrogen receptor a (ERa) serine 118 and high phosphorylation of ERa serine 167 improve survival in ER-positive breast cancer (2008) (18)
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study (2017) (18)
Localization of gelatinolytic activity can be detected in Breast Cancer tissues by filmin situ zymography (2001) (18)
Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival (2013) (17)
Lenvatinib (2018) (17)
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (2013) (17)
Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer (2008) (17)
The role of stat5 in estrogen receptor-positive breast cancer (2002) (17)
Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling (2018) (17)
Clinical significance of estrogen receptor β in breast cancer (1999) (17)
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer (2015) (17)
Comparison of five different antibodies in the immunohistochemical assay of estrogen receptor α in Human breast cancer (2000) (16)
Triple negative breast cancer: clinicopathological characteristics and treatment strategies (2009) (15)
Roles of long noncoding RNAs in chromosome domains (2017) (15)
Differential impact of body mass index and its change on the risk of breast cancer by molecular subtype: A case-control study in Japanese women (2012) (14)
Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. (2021) (14)
Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. (2018) (14)
Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer. (2020) (14)
Telomerase activity in esophageal squamous cell carcinoma: Down‐regulation by chemotherapeutic agent (2002) (13)
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients (2017) (13)
Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer. (2015) (13)
Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor (2010) (13)
Clinical significance of androgen receptor and its phosphorylated form in breast cancer. (2013) (13)
Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer. (1997) (13)
Low expression of the snail gene is a good prognostic factor in node-negative invasive ductal carcinomas. (2006) (12)
Differential predictive factors for cardiovascular events in patients with or without cancer history (2019) (12)
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer (2015) (11)
[The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis]. (1995) (11)
GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development (2016) (11)
Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer (2004) (11)
Detection of DNA fragmentation in human breast cancer tissue by an antibody specific to single-stranded DNA (1998) (10)
Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women (2017) (10)
Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse. (2009) (10)
Expression of estrogen receptor α exon 5 and 7 deletion variant in human breast cancers (2000) (10)
Menopausal status should be taken into consideration for patients with luminal a breast cancer in terms of the effect of differential biology on prognosis. (2013) (9)
Quantitative determination of insulin-like growth factor 1 receptor mRNA in formalin-fixed paraffin-embedded tissues of invasive breast cancer (2012) (9)
Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial (2019) (9)
Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer (2011) (9)
Factors involved in early lenvatinib dose reduction: a retrospective analysis (2018) (9)
The clinical value of microsatellite instability and a loss in heterozygosity in sporadic breast cancers (1997) (9)
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor (2015) (8)
p33ING1b and estrogen receptor (ER) α (2004) (8)
Metachronous Primary Hyperparathyroidism Due to a Parathyroid Adenoma and a Subsequent Carcinoma: Report of a Case (2001) (8)
[A case of stromal sarcoma of the breast occurring after augmentation mammaplasty]. (1988) (8)
2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission (2014) (8)
A case report of paraneoplastic neurological syndrome associated with occuft breast cancer (2006) (7)
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin–docetaxel neoadjuvant chemotherapy: a cohort study (2009) (7)
Telomerase Activity Levels for Evaluating the Surgical Margin in Breast-Conserving Surgery (2001) (7)
APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer (2018) (7)
Alterations and polymorphisms of the estrogen receptor gene in breast cancer (1997) (6)
A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey (2019) (6)
Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer (2017) (6)
ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study. (2018) (6)
Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer (2004) (6)
[Management for treatment-induced adverse reaction--chemotherapy]. (2012) (6)
Recurrent breast cancer at 21 years after resection detected by serum tumor markers and manifested as dermatomyositis (1994) (5)
Divisional role of quantitative HER2 testing in breast cancer (2015) (5)
BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study (2020) (5)
Clinical significance of cathepsin D assay in breast cancer tissues (1995) (5)
Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: Report of a case (2011) (5)
Proliferative cell nuclear antigen expression in follicular tumours of the thyroid with special reference to oxyphilic cell lesions (2004) (5)
Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment (2001) (5)
Low frequency loss of heterozygosity in theBRCA1 region in Japanese sporadic breast cancer (1996) (5)
Corrigendum: ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling (2015) (4)
QS106. Sentinel Lymph Node Biopsy Using SPECT-CT Fusion Imaging in Patients With Breast Cancer and Its Clinical Usefulness (2009) (4)
Are graduating residents sufficiently competent? Results of a national gap analysis survey of program directors and graduating residents in Japan (2020) (4)
A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character (2013) (4)
dPCR Mutational Analyses in Cell-Free DNA: A Comparison with Tissues. (2019) (4)
The role of exosomal microRNAs; focus on clinical applications in breast cancer (2019) (4)
Biweekly paclitaxel in patients with metastatic breast cancer (2003) (4)
Clinical usefulness of oral combination chemotherapy of 5′;-deoxy-5-fluorouridine (5′;-DFUR) and cyclophosphamide for metastatic Breast Cancer (2006) (4)
p33ING1b and estrogen receptor (ER) alpha. (2004) (4)
The clinical value of serum CA15-3 assay postoperatively in breast cancer patients (1989) (4)
[Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer]. (2005) (4)
Correlation between clinical tumor stiffness by elastography and response to neoadjuvant chemotherapy in patients with breast cancer. (2014) (4)
Readministration of tamoxifen after adjuvant therapy for recurrent breast cancer (2000) (3)
Current topics and perspectives in the treatment of endocrine-related cancers (2008) (3)
The treatment of uterine leiomyosarcoma: clinical outcomes of 18 cases and the effectiveness of chemotherapy. (2011) (3)
Chemotherapy for Patients with Renal Dysfunction (2017) (3)
Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer (2016) (3)
[Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer]. (1996) (3)
TWO CASES OF DIABETIC MASTOPATHY (2001) (3)
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer : a postmarketing observational study (2017) (3)
Primary adrenocortical tumors in autopsy records —A survey of “cumulative reports in Japan” from 1973 to 1984— (1991) (3)
Consecutively occurring multiple fibroadenomas of the breast distinguished from phyllodes tumors by clonality analysis of stromal tissue (1999) (3)
Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy. (2011) (3)
Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum (2021) (2)
Abstract P1-12-01: Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095) (2012) (2)
Molecular and Cellular Pathobiology Tumor Cell – Derived Angiopoietin-like Protein ANGPTL 2 Is a Critical Driver of Metastasis (2012) (2)
Abstract P1-12-03: The STAGE Study: A Phase III Comparison of Anastrozole Plus Goserelin with Tamoxifen Plus Goserelin as Pre-Operative Treatments in Premenopausal Breast Cancer Patients (2010) (2)
PTIP Associated protein 1, PA1, Is an Independent Prognostic Factor for Lymphnode Negative Breast Cancer (2013) (2)
Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. (2009) (2)
Successful ethinylestradiol therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies (2016) (2)
Potential advantage of studying preoperative sentinel node mapping with three-dimensional images by a hybrid single photon emission CT (SPECT)/CT system for breast cancer (2007) (2)
[Two cases of stage IV breast cancer with severe hypercalcemia]. (2006) (2)
Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors. (2018) (2)
Differential role of MACC 1 expression and its regulation of the HGF / c ‐ Met pathway between breast and colorectal cancer (2015) (2)
Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy (2015) (2)
Predictive and prognostic significance of BRCAness in HER2-negative breast cancer (2022) (2)
[Expression of E-cadherin in thyroid neoplastic tissues and its correlation with malignant and metastatic potential]. (1995) (2)
92OEverolimus (EVE) + letrozole (LET) in Asian patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Results of a subgroup analysis from the BOLERO-4 study (2017) (2)
Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval. (2004) (2)
Aromatase inhibitor-induced joint symptom in patients with breast cancer (2007) (2)
A CASE OF MUCOCELE-LIKE TUMOR OF THE BREAST (2000) (2)
Expression of estrogen receptor alpha exon 5 and 7 deletion variant in human breast cancers. (2000) (2)
Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report (2016) (2)
[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)]. (2014) (2)
The localization of HER 4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER + HER 2-breast cancer (2014) (1)
A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer (2013) (1)
The Clinical Value of Serum CA 15-3 Assay Postoperatively in Breast Cancer Patients (1)
Incidence and clinical relevance of ESR1 mutations in estrogen receptor positive breast cancer patients. (2017) (1)
Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer (2008) (1)
Abstract 06: A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. (2012) (1)
Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues (1996) (1)
Abstract P6-01-20: A role of MACC1 expression and its regulation of the HGF/c-Met pathway in breast cancer (2015) (1)
Estrogen receptor α and β expression in human breast cancer tissues analysed by RT-PCR (1998) (1)
Abstract P3-04-15: Ethinylestradiol treatment downregulates ER and upregulates PgR; Immunohistochemical analysis in postmenopausal breast cancer tissues after prior long-term estrogen-deprivation therapy (2015) (1)
P5-03-02: Aurora A Is Closely Linked to an Aggressive Phenotype of Breast Cancer. (2011) (1)
[Prognostic significance of loss of heterozygosity in breast cancer]. (1998) (1)
A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism. (2018) (1)
A case of pancreatic cancer including osteoclast-like gaiant cells. (1990) (1)
P1-09-04: A Genetic Predictor for Breast Cancer Risk in a Japanese Population. (2011) (1)
BRCAness and prognosis of triple-negative breast cancer patients treated with neoadjuvant chemotherapy. (2017) (1)
A CASE OF SPINDLE CELL CARCINOMA OF THE BREAST WITH MULTINUCLEATED GIANT CELLS (1996) (1)
[A case of spindle cell carcinoma of the breast including metaplastic lesion with poor prognosis]. (2009) (1)
Abstract P6-05-06: Serum estradiol levels in postmenopausal ER+/PR- breast cancer are lower than those in postmenopausal ER+/PR+ (2012) (1)
Bolero-2: A Randomized Phase III Study of Everolimus in Combination with Exemestane: Results of the Japanese Subgroup Analysis (2012) (1)
Abstract P1-02-13: Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no-recurrence (2017) (1)
P1-19-4AN EVALUATION OF THE INCIDENCE OF ADVERSE EVENTS BY SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF BORTEZOMIB (2014) (1)
[Clinical value of gene diagnosis in breast cancer]. (1998) (1)
Neoadjuvant anastrozole or tamoxifen for premenopausal breast cancer: Ki67 expression data from the STAGE study. (2011) (1)
Invasion and metastasis of breast cancer matrix - Metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) (1995) (1)
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (2013) (1)
ISY-24-3ESR1 gene alterations related to endocrine resistance in metastatic breast cancer (2016) (0)
[Treatment guideline for breast cancer and SERM-treatment]. (2007) (0)
Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival (2013) (0)
Association of p53 codon 72 polymorphism with resistance to adjuvant therapy in primary breast cancer (2007) (0)
A case of premenopausal breast cancer with symptomatic cerebellar metastasis successfully treated by systemic endocrine therapy alone: relationship to biological features (2017) (0)
[The marginal utility of affinity chromatography using immobilized estradiol in the purification of human uterine estrogen receptor]. (1984) (0)
Abstract P6-09-48: Development of a predictive model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer (2017) (0)
A case of pancreatic ascites successfully treated with peritoneal lavage. (1990) (0)
Abstract P3-11-02: A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study) (2018) (0)
P3-03-01: Low Expression of microRNA-210 Is an Independent Good Prognostic Factor in Japanese Triple-Negative Breast Cancer Patients. (2011) (0)
A CASE OF MALIGNANT PHYLLODES TUMOR OF THE BREAST DIAGNOSED BY ASPIRATION BIOPSY CYTOLOGY (1998) (0)
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study (2018) (0)
THE MULTIMODAL TREATMENT FOR BREAST CANCER WITH BRAIN METASTASES (1991) (0)
[GENDER EQUALITY IN BREAST SURGERY]. (2016) (0)
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer (2018) (0)
[The localization of estrogen receptor (ER) in target tissues as visualized by immunoperoxidase method using anti-ER antibody]. (1985) (0)
Clinical usefulness of ATBF-1-A expression in breast cancer as a prognostic and predictive marker (2006) (0)
A LONG-TERM SURVIVING CASE OF BREAST CANCER AFTER BRAIN METASTASIS (1996) (0)
A phase I/II dose-escalation study of weekly paclitaxel in combination with 5'-deoxy-5-fluorouridine for advanced or recurrent breast cance. (2004) (0)
Abstract P6-07-07: Clinical significance ofESR1mutations using droplet digital polymerase chain reaction assay in 325 breast cancer samples: (2016) (0)
Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer : ... (2019) (0)
[Endocrine responsiveness based on expression levels of ki67]. (2012) (0)
Abstract 1583: Clinical significance ofPIK3CA,AKT1, andESR1mutation in plasma cell-free DNA from estrogen receptor-positive breast cancer patients (2018) (0)
A CASE OF LATELY RECURRENT BREAST CANCER RECOVERED FROM TRANSVERSAL UPPER THORACIC SPINAL CORD LESION (1992) (0)
[A case of male breast cancer with special reference to the hormonal environment during chemoendocrine therapy]. (1985) (0)
Abstract P3-05-10: Non-coding RNAs derived from near theESR1gene acts as a transcriptional regulator during estrogen deprivation adaptation of ER positive breast cancer cells (2016) (0)
Extended surgery for malignant tumors invading upper mediastinum (2003) (0)
“BRCAness”; a potential predictor needing the additional therapeutics (2017) (0)
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients (2017) (0)
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial (2017) (0)
CHANGES OF SERUM c-erbB-2 PROTEIN VALUES IN PATIENTS WITH RECURRENT BREAST CANCER (1993) (0)
A CASE OF GIANT LIPOMA OF THE BREAST (1997) (0)
OS1. gastric cancer (2012) (0)
[Predictive factors of hormonal therapy in breast cancer]. (2006) (0)
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (0)
Ratio of Expression of p16INK4a to p14ARF Correlates with the Progression of Non‐small Cell Lung Cancer (2002) (0)
Abstract 700: Reduced CYLD expression is an independent prognostic factor in breast cancer: A possible link with RANKL-RANK signaling (2012) (0)
Effectiveness of thyroid hormone rectal suppositories in thyroidectomized patients (1998) (0)
Evaluation of an amplicon-based custom gene panel for the diagnosis of hereditary tumors. (2020) (0)
A CASE OF PHEOCHROMOCYTOMA CLINICALLY MANIFESTED AFTER A 10-YEAR OBSERVATION SINCE DIAGNOSED AS ADRENAL INCIDENTALOMA (2000) (0)
Abstract 3466: Reduced expression of CYLD is an independent prognostic factor in breast cancer and confers treatment resistance and migratory activityin vitro. (2013) (0)
Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
THE INFLUENCE OF ANESTHESIA METHOD ON CREATINE PHOSPHOKINASE (CPK) AFTER APPENDECTOMY (1991) (0)
PROGNOSIS OF A CASE WITH A DIFFUSE SCLEROSING VARIANT OF PAPILLARY THYROID CARCINOMA AFTER TREATMENT WITH PACLITAXEL (2002) (0)
A case of superior mesenteric arterial occlusion successful treated with thrombectomy. (1988) (0)
Abstract A44: Clinical significance of ESR1 mutations by cell-free DNA in recurrent/metastatic breast cancer (2016) (0)
Abstract 3654: Associations of body mass index and its change with breast cancer risk by molecular subtypes: a case-control study in Japanese women. (2013) (0)
[Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]. (2007) (0)
Abstract P1-14-04: Subsequent endocrine therapy after becoming to resistance of ‘estrogen therapy’ is beneficial as a salvage treatment for the late stage metastatic breast cancer (2013) (0)
Current conditions and issues of physicians and working conditions at institutions accredited by the Japanese Breast Cancer Society (2019) (0)
Association of response to neoadjuvant chemotherapy (NAC) in premenopausal patients with hormone receptor-positive early breast cancer with chemotherapy-induced ovarian function suppression by NAC. (2012) (0)
INFLAMMATORY BREAST RECURRENCE AFTER PREOPERATIVE CHEMOTHERAPY FOLLOWED BY PATHOLOGICAL COMPLETE RESPONSE (2008) (0)
CLINICAL STUDIES OF CONGENITAL CERVICAL CYSTS AND FISTULAS (1992) (0)
A CASE OF OXYPHILIC CELL ADENOMA (HURTHLE CELL ADENOMA) OF THYROID WITH A SPECIFIC SCINTIGRAM (1990) (0)
Abstract LB-256: Estrogen and its receptors alpha and beta in different stages of breast carcinogenesis. (2013) (0)
Lenvatinib (2018) (0)
Is there disparity between regions and facilities in surgical resident training in Japan? Insights from a national survey (2020) (0)
Abstract P6-09-46: A comprehensive analysis of GNAS DNA copy number, levels of mRNA and protein expression in primary breast cancer (2017) (0)
[Clinicopathological value of ER alpha, ER beta and those isoforms in breast cancer]. (2000) (0)
HIF-1alpha is closely linked to an aggressive phenotype in breast cancer (2006) (0)
Rationale for salvage therapy with high-dose selective estrogen receptor modulator after treatment failure of aromatase inhibitors in breast cancer (2008) (0)
PO67 CLINICAL BENEFIT OF ETHINYLESTRADIOL AS A SALVAGE ENDOCRINE THERAPY FOR THE HEAVILY PRETREATED METASTATIC BREAST CANCER (2013) (0)
0142 Feasibility study of fluorouracil/epirubicin/cyclophosphamide (FEC75) followed by docetaxel (DOC) as adjuvant chemotherapy in Japanese patients with node positive breast cancer (2009) (0)
A CASE OF PHYLLODES TUMOR IN A JUVENILE WHICH PRESENTED DIFFICULTY IN DIFFERENTIATION FROM GIANT FIBROADENOMA (1997) (0)
Abstract P4-09-01: FGFR1 protein expression is associated with prognosis in primary breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression (2016) (0)
STUDY OF THYROID CARCINOMA WITH SQUAMOUS METAPLASIA (1994) (0)
P213 Neoadjuvant nab-paclitaxel followed by FEC for operable breast cancer: KBC-SG 1103 trial (2015) (0)
Abstract P6-09-06: BRCAness as a prognostic marker in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: A multicenter retrospective study (2019) (0)
415 Comparison of two Phase II trials evaluating three dosing regimens of fulvestrant in Japanese vs non-Japanese postmenopausal women with advanced breast cancer (FINDER1 and FINDER2) (2010) (0)
The serological assessment of therapeutic effects and relapse by tumor markers in patients with advanced or recurrent breast cancer (1992) (0)
Abstract P5-01-13: Poly(I:C), an innate adjuvant receptor ligand, can induce the antitumor effects on human breast cancer cells (2013) (0)
[HOSPITAL EXCHANGE PROGRAM FOR YOUNG SURGEONS]. (2017) (0)
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. (2017) (0)
Abstract P2-14-03: “Ethinylestradiol” is beneficial for postmenopausal advanced breast cancer patients heavily pre-treated with endocrine agents (2012) (0)
[I. ESR1 Gene Alteration and Hormone Resistance in Breast Cancer]. (2016) (0)
P092 QOL score changes in breast cancer patients: 2-year vs. 3-or-more-year administration of leuprorelin (2015) (0)
Thanking All Peer Reviewers. (2019) (0)
Satellite Symposia (2012) (0)
[Practical use of a guideline for examination and treatment for breast cancer]. (2007) (0)
Abstract A40: ESR1 gene alterations in the metastatic breast cancer with resistance to aromatase inhibitor (2016) (0)
A LONG-TERM SURVIVING CASE OF ADVANCED BREAST CANCER WITH LYMPHANGITIS TYPE LUNG METASTASIS (1992) (0)
Midkine in the plasma as a novel breast cancer marker. (2010) (0)
Subsequent endocrine therapy after resistance to ethinylestradiol treatment for the late-stage metastatic breast cancer: A retrospective cohort study. (2014) (0)
Clinical usefulness of high-dose toremifene for patients failed by treatment with aromatase inhibitor (2008) (0)
43PTHE HIGH DSS1 EXPRESSION INVOLVED IN BRCA2 STABILITY IS A MARKER FOR BREAST CANCER OF POOR PROGNOSIS (2014) (0)
Predictors of Response to Exemestane as Primary Endocrine Therapy in Estrogen Receptor-Positive Breast Cancer. (2009) (0)
Abstract P5-11-12: Clinical value ofESR1mutations from cell free DNA in ethynil estradiol treatment for metastatic breast cancer (2020) (0)
Baseline neutrophil-to-lymphocyte ratio and absolute lymphocyte count in patients with HER2-negative breast cancer treated with eribulin may predict overall survival. (2021) (0)
A CASE OF CARCINOMA IN PLEOMORPHIC ADENOMA IN THE SUBMANDIBULAR GLAND WITH CARDIAC METASTASIS (1998) (0)
Abstract P1-02-09: Clinical significance of sequential measurements ofESR1mutations in plasma cell-free DNA in estrogen receptor positive recurrent metastatic breast cancer patients (2017) (0)
IS2. Breast Cancer (2012) (0)
STUDY OF INTRAOPERATIVE RAPID INSULIN ASSAY IN THE DISTAL PANCREATECTOMY FOR HYPOGLYCEMIA (1990) (0)
Abstract P1-14-01: Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior non-steroidal aromatase inhibitor treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR ex study) (2013) (0)
A 9-Gene-Based Molecular Prognostic Model Precisely Predicts Survival and Treatment Response in Breast Cancer Patients (2022) (0)
[Change and perspective in endocrine therapy]. (2012) (0)
Clinical Significance of Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Outpatient'S Chemotherapy Center (2012) (0)
A CASE OF BILATERAL FIBROMATOSIS OF THE BREAST (2003) (0)
P3–030DOES LOCAL ANESTHETIC PATCH REDUCE THE INJECTION SITE PAIN OF FULVESTRANT IN POSTMENOPAUSAL BREAST CANCER? (2013) (0)
Abstract P3-13-05: Estrogen Receptor-Positive Breast Cancer in Japanese Women: Trends in Incidence, Characteristics and Prognosis (2010) (0)
Abstract P3-07-11: High activation of PI3K pathway defined by PIK3CA mutation, PTEN, and INPP4B expression are associated with trastuzumab efficacy in HER2-positive breast cancer (2016) (0)
BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. (2012) (0)
A Case of Superior Mesenteric Artery Occlusion Successfully Treated without Bowel Resection (1990) (0)
[Prediction for efficacy of endocrine therapy for breast cancers using gene profiling]. (2007) (0)
Clinical significance of anti-p53 antibody in the sera in patients with breast cancer. (2011) (0)
Mouse mammary gland reconstitution with extrinsic gene-transferred mammary epithelial cells in vitro and in vivo (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hirotaka Iwase?

Hirotaka Iwase is affiliated with the following schools:

Hirotaka Iwase's Academic­Influence.com Rankings

Hirotaka Iwase's Degrees

Why Is Hirotaka Iwase Influential?

Hirotaka Iwase's Published Works

Published Works

What Schools Are Affiliated With Hirotaka Iwase?

Hirotaka Iwase's AcademicInfluence.com Rankings